Web-based management program for obesity
Official title: HealthyWeightHub.fi: Web-based Management of Obesity in a Real-life Clinical Setting
Run by Helsinki University Central Hospital · NCT04019249 · Data updated 2026-11-12
This study tests a year-long online program that helps people manage obesity by combining nutrition, exercise, and support from a personal coach.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 6000 (estimated) |
| Sponsor | Helsinki University Central Hospital Academic / other |
| Locations | 1 site (Helsinki) |
| Status | Recruiting |
| Started | October 1, 2016 |
| Main results expected | December 31, 2030 |
| Study ends | December 31, 2030 |
| Registry record updated | March 18, 2022 |
| Trial ID | NCT04019249 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults over 18 years old with a body mass index (BMI) of 25 kg/m² or higher who can access the internet.
✕Probably not a fit
Patients with severe illnesses requiring specialized care or those who are pregnant or breastfeeding may not benefit from this program.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study evaluates the effectiveness of the HealthyWeightCoaching (HWC) program, a 12-month web-based intervention designed to manage obesity in a real-life clinical setting. The program combines nutrition, physical activity, and cognitive behavioral approaches, with a focus on acceptance and commitment therapy. Participants receive automated, interactive support along with a personal coach to guide them through the program. Enrollment is facilitated through referrals from various healthcare sources across Finland.
Why it matters
Potential benefit: If successful, this program could provide an accessible and effective method for managing obesity and improving health outcomes for patients.
How similar studies have gone: Other studies have shown promise in using online programs for obesity management, indicating that this approach is both relevant and potentially effective.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * age over 18 years * body mass index (BMI) ≥ 25 kg/ m² * the possibility to use a computer and /or a smartphone with access to the internet * willingness to participate in the digital treatment program Exclusion Criteria: * diagnosed severe illness requiring assessment from the specialty care obesity center * pregnancy or breastfeeding
Where it's running
-
University of Helsinki
Helsinki, Finland Recruiting
Study contacts
- Principal investigator: Kirsi Pietiläinen, MD-PhD — Helsinki University Central Hospital
- Study coordinator: Kirsi Pietiläinen, MD-PhD
- Email: kirsi.pietilainen@helsinki.fi
- Phone: +358505992295
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Ocular Changes in People Using Tirzepatide or Semaglutide
This study checks whether eye structure and blood vessels change in adults with obesity who are taking semaglutide or tirzepatide as part of routine care.
-
Whole-Body Vibration Training in Women With Obesity With and Without Type 2 Diabetes
This study tests whether eight weeks of supervised whole-body vibration training changes ankle muscle activity and walking performance in women with obesity, comparing those with and without type 2 diabetes.
-
Berobenatide for knee pain in adults who are overweight or with obesity
This study tests berobenatide vs. placebo to see if it reduces knee pain and improves function while helping with weight in adults with knee osteoarthritis and overweight/obesity.
-
Weekly berobenatide for knee osteoarthritis in adults who are overweight or obese
This study tests whether weekly berobenatide helps reduce knee pain and improve function, while also affecting body weight, in adults with knee osteoarthritis who are overweight or obese (with or without type 2 diabetes).
-
Maridebart cafraglutide in people who switched from weekly GLP-1 receptor agonists
This study tests how much maridebart cafraglutide appears in the blood after people with overweight or obesity switch from weekly GLP-1 receptor agonists.
-
EloraTZP for weight loss in adults with overweight/obesity and type 2 diabetes
This trial tests whether a coformulation of eloralintide and tirzepatide helps people with obesity or overweight and type 2 diabetes lose weight compared with tirzepatide alone.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.